Get started
Author

Charlotte van Kesteren

Observed names: C Van Kesteren, C van Kesteren, C. Van Kesteren, C. can Kesteren, C. van Kesteren, Charlotte Kesteren, Charlotte Van Kesteren, van Kesteren, Charlotte
Observed institutions: Leiden University, Utrecht University, Slotervaartziekenhuis, University Medical Center, The Netherlands Cancer Institute, University Medical Center Utrecht, Albert Schweitzer Ziekenhuis, Princess Máxima Center, Wilhelmina Children's Hospital, Erasmus University Rotterdam
ORCID: 0000-0001-9071-6421
Observed ORCID: 0000-0001-9071-6421
OpenAlex ID: A5078051014
Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis
2015 · Rick Admiraal, Charlotte van Kesteren, et al. · The Lancet Haematology · 292
PDF
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis
2017 · Rick Admiraal, Stefan Nierkens, et al. · The Lancet Haematology · 222
PDF
Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation
2016 · Rick Admiraal, Caroline A. Lindemans, et al. · Blood · 167
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
2002 · N E Schoemaker, C van Kesteren, et al. · British Journal of Cancer · 120
PDF
Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing
2014 · Rick Admiraal, Charlotte van Kesteren, et al. · Clinical Pharmacokinetics · 102
Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation
2007 · Imke H. Bartelink, Robbert G.M. Bredius, et al. · Transplantation and Cellular Therapy · 86
PDF
Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
2003 · C. Twelves, K. Hoekman, et al. · European Journal of Cancer · 84
Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab
2014 · Laura Willemsen, Cornelia M. Jol-van der Zijde, et al. · Transplantation and Cellular Therapy · 82
PDF
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
2002 · Miguel A Villalona-Calero, S Gail Eckhardt, et al. · PubMed · 82
Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes
2019 · J. B. Langenhorst, C. van Kesteren, et al. · Blood Advances · 81
Development of an optimal lidocaine infusion strategy for neonatal seizures
2006 · Mirte M. Malingré, Linda G. M. Van Rooij, et al. · European Journal of Pediatrics · 80
Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II
1999 · C van Kesteren · Cardiovascular Research · 80
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
2000 · C van Kesteren, E Cvitkovic, et al. · PubMed · 79
Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
2018 · Jurgen B. Langenhorst, Thomas P. C. Dorlo, et al. · Clinical Pharmacokinetics · 74
PDF
Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults
2012 · Imke H. Bartelink, Charlotte van Kesteren, et al. · Therapeutic Drug Monitoring · 63
Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling
2013 · Rick Admiraal, Charlotte van Kesteren, et al. · Archives of Disease in Childhood · 54
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
2005 · Charlotte van Kesteren, Anthe S. Zandvliet, et al. · Investigational New Drugs · 49
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study
2002 · Charlotte van Kesteren, Chris Twelves, et al. · Anti-Cancer Drugs · 45
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC–MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning
2017 · Arjen. M. Punt, Jurgen B. Langenhorst, et al. · Journal of Chromatography B · 42
PDF
Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
2019 · Rick Admiraal, Cornelia M. Jol-van der Zijde, et al. · Clinical Pharmacokinetics · 37
PDF
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer
2002 · Charlotte van Kesteren, Jos H Beijnen, et al. · Anti-Cancer Drugs · 36
A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance
2020 · Jurgen B. Langenhorst, Jill Boss, et al. · British Journal of Clinical Pharmacology · 29
PDF
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
2001 · Rolf W Sparidans, Hilde Rosing, et al. · Anti-Cancer Drugs · 28
Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review
2023 · Charlotte Sikking, Kelly L Niggebrugge-Mentink, et al. · The Oncologist · 24
PDF
Population Pharmacokinetics of Allopurinol in Full-Term Neonates With Perinatal Asphyxia
2006 · Charlotte van Kesteren, Manon J. N. L. Benders, et al. · Therapeutic Drug Monitoring · 23
Works count: 67
Citation count: 2,234
H-index: 23
I10-index: 33
Year
Topic
Type